The Money Blind: How to Stop Industry Bias in Biomedical Science, Without Violating the First Amendment
Christopher T. Robertson
Harvard Law School; University of Arizona - James E. Rogers College of Law; Harvard University - Edmond J. Safra Center for Ethics
37 American Journal of Law and Medicine 358 (2011)
Arizona Legal Studies Discussion Paper No. 13-42
The pharmaceutical and medical device industries use billions of dollars to support the biomedical science that physicians, regulators, and patients use to make healthcare decisions—the decisions that drive an increasingly large portion of the American economy. Compelling evidence suggests that this industry money buys favorable results, biasing the outcomes of scientific research. Current efforts to manage the problem, including disclosure mandates and peer reviews, are ineffective. A blinding mechanism, operating through an intermediary such as the National Institutes of Health, could instead be developed to allow industry support of science without allowing undue influence. If the editors of biomedical journals fail to mandate that industry funders utilize such a solution, the federal government has several regulatory levers available, including conditioning federal funding and direct regulation, both of which could be done without violating the First Amendment.
Number of Pages in PDF File: 31
Keywords: biomedical science, bias, healthcare decisions, disclosure, blinding mechanism, regulation, funding, First AmendmentAccepted Paper Series
Date posted: September 1, 2013
© 2013 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo3 in 0.489 seconds